论文部分内容阅读
美国Oncor公司1月5日宣布获得FDA批准癌基因HER-2/neu检测试剂合上市。该试剂目前旨在用于乳癌手术后的癌组织检验,以预测复发机
Oncor, the United States, announced on January 5 that it had received the FDA-approved oncogene HER-2/neu test reagents for market launch. This reagent is currently intended for the detection of cancer tissue after breast cancer surgery to predict recurrence